Literature DB >> 8420736

Heparin in experimental hyperdynamic sepsis.

J Meyer1, C S Cox, D N Herndon, H Nakazawa, C W Lentz, L D Traber, D L Traber.   

Abstract

OBJECTIVE: To evaluate the hypothesis that heparin administration increases cardiac output and improves oxygenation in experimental hyperdynamic sepsis in sheep.
DESIGN: Prospective trial.
SETTING: Laboratory at a large university-affiliated medical center.
SUBJECTS: A total of 14 sheep weighing 28 to 44 kg.
INTERVENTIONS: All 14 chronically instrumented sheep received a continuous infusion of Escherichia coli endotoxin (10 ng/kg/min) over 24 hrs. Seven sheep received a fixed bolus of beef lung heparin (5000 units) every 4 hrs intravenously. The other seven sheep served as controls.
MEASUREMENTS AND MAIN RESULTS: The heparinized animals showed a triphasic cardiovascular response. Cardiac index increased (p < .05), and systemic vascular resistance index decreased (p < .05) at 2 hrs after the start of the endotoxin infusion (early phase, 0 to 2 hrs). Both variables returned to approximately baseline levels at 4 hrs (second period, 2 to 4 hrs). A hyperdynamic state (in terms of an increased cardiac index), a decreased systemic vascular resistance index, and a decreased mean arterial pressure (MAP) (p < .05 for all) was observed in the third phase (8 to 24 hrs). In the control group, cardiac index, systemic vascular resistance index, and MAP showed no changes in the first period, but a slight decrease in cardiac index and a slight increase in systemic vascular resistance index in the second period. The onset of the hyperdynamic state was less pronounced in the control group and cardiac index was lower (p < .05); likewise, systemic vascular resistance index was increased (p < .05) when compared with heparinized animals. Both groups developed pulmonary hypertension during the endotoxin infusion. The gas exchange in the heparin group was significantly impaired in the first and second periods, but returned to baseline levels in the hyperdynamic phase, whereas the oxygenation of the nonheparinized animals showed only minor changes in the first and second phases, but deteriorated significantly during the third phase of endotoxemia.
CONCLUSIONS: In this experimental model of hyperdynamic sepsis, heparin significantly influenced the cardiopulmonary performance. Heparin preserved gas exchange and increased cardiac output but lowered systemic vascular resistance and MAP in the hyperdynamic state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420736     DOI: 10.1097/00003246-199301000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes.

Authors:  M Heinzelmann; M Miller; A Platz; L E Gordon; D O Herzig; H C Polk
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

2.  Heparin protects against septic mortality via apoE-antagonism.

Authors:  Kelley I Chuang; Briana Leung; Nancy Hsu; Hobart W Harris
Journal:  Am J Surg       Date:  2011-07-08       Impact factor: 2.565

3.  Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism.

Authors:  A Salas; M Sans; A Soriano; J C Reverter; D C Anderson; J M Piqué; J Panés
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

4.  Neutrophil CD18 expression and blockade after traumatic shock and endotoxin challenge.

Authors:  T C Fabian; M A Croce; R M Stewart; M E Dockter; K G Proctor
Journal:  Ann Surg       Date:  1994-10       Impact factor: 12.969

5.  A randomized clinical trial of unfractioned heparin for treatment of sepsis (the HETRASE study): design and rationale [NCT00100308].

Authors:  Fabián Jaimes; Gisela De la Rosa; Clara Arango; Fernando Fortich; Carlos Morales; Daniel Aguirre; Pablo Patiño
Journal:  Trials       Date:  2006-05-26       Impact factor: 2.279

6.  Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats.

Authors:  Toshiaki Iba; Taku Miyasho
Journal:  Crit Care       Date:  2008-07-06       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.